Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab

Clin Exp Dermatol. 2005 Mar;30(2):134-6. doi: 10.1111/j.1365-2230.2004.01681.x.


A 63-year-old man with chronic lymphocytic leukaemia developed pyoderma gangrenosum following minor trauma to the leg. He required intensive inpatient management with a multitude of treatments including larval therapy, surgical debridement, ciclosporin, methotrexate, thalidomide, pulsed intravenous methylprednisolone and high-dose intravenous immunoglobulin, clofazamine and high dose oral corticosteroids, none of which were helpful. Treatment complications included steroid-induced diabetes, Cushing's syndrome and perforated peptic ulcer. The pyoderma remained refractory to treatment and continued to extend until he received intravenous infliximab 5 mg/kg at weeks 0, 2 and 6.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Infliximab
  • Leukemia, Lymphocytic, Chronic, B-Cell / complications
  • Male
  • Middle Aged
  • Pyoderma Gangrenosum / drug therapy*
  • Pyoderma Gangrenosum / etiology
  • Pyoderma Gangrenosum / pathology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors


  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab